Arbutus Biopharma Faces Patent Revocation in Europe

Arbutus Biopharma Corp has had its European patent EP 2279254 revoked by the European Patent Office. The company is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for chronic hepatitis B virus (HBV) infection. Its HBV product pipeline includes Imdusiran and AB-101, which target various steps in the HBV viral lifecycle. Arbutus Biopharma Corp's RNAi therapeutic and oral PD-L1 inhibitor product candidates aim to provide a functional cure for patients with cHBV infection.